Ocumetics Director and CEO, Dean Burns covers important updates on our first-in-human (FIH) study and what lies ahead. Topics include:

  1. Encouraging outcomes from initial surgeries
  2. Next steps to complete the FIH study
  3. Live Q&A session with Dean Burns

https://youtu.be/rWQnOaq6sVE

  • Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million Dear Ocumetics Investors,  I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first

  • Understanding the significance of the biocompatibility journey and why it’s essential for US FDA Approval  Earlier this week, Ocumetics sent out a press release announcing that we completed our three-month biocompatibility study and received very favorable results. Receiving favorable results in this study is a critical aspect in the field of health care and medical

  • Tired of glasses?  New lens technologies might offer a better way to see and experience the world. Anyone who relies on corrective eyewear has experienced its drawbacks. Maybe you are approaching your 50’s and need glasses to see up close. Maybe you left your reading glasses at home and find yourself asking for help deciphering

  • Ocumetics believes its accommodating lens technology could transform the eye care industry. Dr. Garth Webb, Ocumetics’ Founder and Chief Scientific Officer, thinks nothing is as beautiful as the lens in the human eye. “It’s this gorgeous, crystal-like orb that hides just behind the pupil,” he says. But it doesn’t stay that way forever. Inevitably, as